Adverse effects of adjuvant endocrine therapy

Adverse effects of adjuvant endocrine therapy

Hormonal therapy is a highly effective and well tolerable treatment of hormone-responsive breast cancer. However, it has some side effects that can affect quality of life and lead to treatment discontinuation. Common side effects of tamoxifen and aromatase inhibitors are discussed in this article: m...

Full description

Bibliographic Details
Main Authors:	E. I. Kovalenko, I. B. Kononenko, A. V. Snegovoi, O. P. Grebennikova, L. V. Manzyuk
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2018-07-01
Series:	Медицинский совет
Subjects:	hormonal therapy side effects tamoxifen aromatase inhibitors
Online Access:	https://www.med-sovet.pro/jour/article/view/2534

Similar Items

Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
by: Roberta Rosso, et al.
Published: (2023-01-01)

Does the Time of Day at Which Endocrine Therapy Is Taken Affect Breast Cancer Patient Outcomes?
by: Ana-Alicia Beltran-Bless, et al.
Published: (2021-07-01)

Neoadjuvant endocrine treatment of women with breast cancer
by: Julian Iturbe, et al.
Published: (2011-09-01)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
by: Butani D, et al.
Published: (2021-11-01)

The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review
by: Leanne Fleming, et al.
Published: (2022-08-01)

The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis
by: Nicola Peddie, et al.
Published: (2021-08-01)

Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives
by: Inga Bekes, et al.
Published: (2023-08-01)

Identifying determinants of adherence to adjuvant endocrine therapy following breast cancer: A systematic review of reviews
by: Adam Todd, et al.
Published: (2024-02-01)

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review
by: Tomás Reinert, et al.
Published: (2016-12-01)

Is the extension of adjuvant hormone therapy for breast cancer justified?
by: V. F. Semiglazov, et al.
Published: (2020-07-01)

Tactics for minimizing risk of increasing estradiol against the background of aromatase inhibitors in combination with gonadotropin releasing hormone agonists in adjuvant therapy for breast cancer in premenopausal patients. Pilot study results
by: I. B. Kononenko, et al.
Published: (2018-11-01)

Switching of Hormone Therapies in Breast Cancer Women
by: Luana Moreira de Medeiros, et al.
Published: (2021-05-01)

Breast ductal carcinoma in situ: a literature review of adjuvant hormonal therapy
by: Stephen Kinsey-Trotman, et al.
Published: (2016-12-01)

The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy
by: Giorgio Dell’Acqua, et al.
Published: (2020-11-01)

Importance of evaluation of ovarian function in women with breast cancer when using endocrinotherapy
by: I. B. Kononenko, et al.
Published: (2018-07-01)

Initiation of Antiresorptive Drug Treatment during Endocrine Therapy for Breast Cancer—A Retrospective Cohort Study of 161,492 Patients in Germany
by: Niklas Gremke, et al.
Published: (2023-03-01)

Is monitoring mean platelet volume necessary in breast cancer patients?
by: Taskaynatan Halil, et al.
Published: (2018-10-01)

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
by: Hao Liao, et al.
Published: (2022-05-01)

Women’s Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions
by: Brittany Humphries, et al.
Published: (2018-06-01)

Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer
by: Li Li, et al.
Published: (2018-10-01)

Risk of developing depression from endocrine treatment: A nationwide cohort study of women administered treatment for breast cancer in South Korea
by: Jooyoung Oh, et al.
Published: (2022-09-01)

Switching to anastrozole plus goserelin vs continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: preliminary results from a randomized trial
by: Li J, et al.
Published: (2018-12-01)

Evaluation of Arthralgia Induced by Aromatase Inhibitor Therapy
by: Gulabi Mese, et al.
Published: (2013-02-01)

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
by: Naiba Nabieva, et al.
Published: (2021-11-01)

Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
by: Rakhshanda Layeequr Rahman, et al.
Published: (2012-10-01)

SYSTEMIC TREATMENT IN DUCTAL CARCINOMA IN SITU
by: Bülent Karagöz, et al.
Published: (2013-04-01)

CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer
by: Malin Dahlgren, et al.
Published: (2023-06-01)

Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation
by: Maha F. Althuwaibi, et al.
Published: (2023-06-01)

Bone mineral density in patient with breast cancer
by: I V Poddubnaya, et al.
Published: (2013-12-01)

A REGENERATIVE APPROACH TO AN ACUTE EXACERBATION OF HIP PAIN FROM AROMATASE INHIBITOR ASSOCIATED MUSCULOSKELETAL SYNDROME AND AROMATASE-INHIBITOR ARTHRALGIAS
by: Christian Vangeison, et al.
Published: (2022-10-01)

Cutaneous sarcoidosis possibly associated with aromatase inhibitors and tamoxifen
by: Tomoya Sawada, MD, et al.
Published: (2023-06-01)

Younger tamoxifen-treated breast cancer patients also had higher risk of endometrial cancer and the risk could be reduced by sequenced aromatase inhibitor use: A population-based study in Taiwan
by: Sung-Chao Chu, et al.
Published: (2020-01-01)

Endometrial Metastasis from Breast Cancer during Adjuvant Endocrine Therapy
by: Fumikata Hara, et al.
Published: (2010-04-01)

Oophorectomy in Premenopausal Patients with Estrogen Receptor-Positive Breast Cancer: New Insights into Long-Term Effects
by: Fatima Khan, et al.
Published: (2023-02-01)

Antiestrogen therapy in recurrent ovarian cancer resulting in 28 months of stable disease: A case report and review of the literature
by: Carter Jori, et al.
Published: (2010-01-01)

Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: A prospective cohort study
by: Yuxin Xie, et al.
Published: (2022-12-01)

The effectiveness of controlled ovarian stimulation with tamoxifen for patients with estrogen‐sensitive breast cancer: A systematic review and meta‐analysis
by: Tsukasa Yoshida, et al.
Published: (2023-01-01)

Anti-estrogen Treatment in Endometrial Cancer: A Systematic Review
by: Willem Jan van Weelden, et al.
Published: (2019-05-01)

Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data
by: Sung Hyouk Choi, et al.
Published: (2020-12-01)

The recent progress of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer therapy
by: Jing Xu, et al.
Published: (2023-07-01)